← Leaderboards
Ravi Salgia
University Of Nebraska Medical Center
$9,622,551
Attributed
$12,825,697
Total exposure
9
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,825,697 · 9
By mechanism
R01$10,535,098 · 5
P01$1,676,247 · 1
R21$379,152 · 2
R29$235,200 · 1
Top collaborators
- Surinder Kumar Batra5 shared
- Maneesh Jain5 shared
- Deric L Wheeler4 shared
- Hedy L Kindler2 shared
Most similar at University Of Nebraska Medical Center
Same institution · by research overlap
- Maneesh Jain$6,905,007
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoSignal TransductionHepatocyte Growth FactorGenesMutatePathway InteractionsAngiogenesisMutantResponseCell MotilityMalignant NeoplasmsIn VitroTumorReceptor Protein-Tyrosine KinasesCell LineMalignant Neoplasm Of LungBiochemicalMigrationMutationLigandsTumor TissueNeoplasm MetastasisBiologicalMediating
Grant awards (41)
Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNC$604,693
R01 · FY2025 · CA
Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer$573,438
R01 · FY2024 · CA
Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNC$571,864
R01 · FY2024 · CA
Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNC$579,028
R01 · FY2023 · CA
Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer$535,359
R01 · FY2023 · CA
Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer$535,359
R01 · FY2022 · CA
Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNC$504,584
R01 · FY2022 · CA
Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer$567,785
R01 · FY2021 · CA
Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer$614,511
R01 · FY2020 · CA
Role of Paxillin in Lung Cancer$318,450
R01 · FY2012 · CA · contact PI
Hepatocyte Growth Factor/c-Met Invovement in Lung EC Barrier Regulation$300,642
P01 · FY2012 · HL · contact PI
Role of c-Met in SCLC and Potential for Novel Therapy$241,067
R01 · FY2012 · CA · contact PI
Role of Paxillin in Lung Cancer$318,071
R01 · FY2011 · CA · contact PI
Hepatocyte Growth Factor/c-Met Invovement in Lung EC Barrier Regulation$300,642
P01 · FY2011 · HL · contact PI
Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)$254,610
R01 · FY2011 · CA · contact PI
Role of c-Met in SCLC and Potential for Novel Therapy$241,037
R01 · FY2011 · CA · contact PI
Hepatocyte Growth Factor/c-Met Invovement in Lung EC Barrier Regulation$361,262
P01 · FY2010 · HL · contact PI
Role of Paxillin in Lung Cancer$327,534
R01 · FY2010 · CA · contact PI
Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)$262,485
R01 · FY2010 · CA · contact PI
Role of c-Met in SCLC and Potential for Novel Therapy$248,460
R01 · FY2010 · CA · contact PI
Novel Targeted Therapy in Pancreatic Cancer$205,920
R21 · FY2010 · CA · contact PI
Hepatocyte Growth Factor/c-Met Invovement in Lung EC Barrier Regulation$353,209
P01 · FY2009 · HL · contact PI
Role of Paxillin in Lung Cancer$327,175
R01 · FY2009 · CA · contact PI
Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)$262,485
R01 · FY2009 · CA · contact PI
Role of c-Met in SCLC and Potential for Novel Therapy$251,380
R01 · FY2009 · CA · contact PI
Role of Paxillin in Lung Cancer$186,827
R01 · FY2009 · CA · contact PI
Novel Targeted Therapy in Pancreatic Cancer$171,600
R21 · FY2009 · CA · contact PI
Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)$98,000
R01 · FY2009 · CA · contact PI
Role of c-Met in SCLC and Potential for Novel Therapy$19,085
R01 · FY2009 · CA · contact PI
Hepatocyte Growth Factor/c-Met Invovement in Lung EC Barrier Regulation$360,492
P01 · FY2008 · HL · contact PI
Role of Paxillin in Lung Cancer$326,831
R01 · FY2008 · CA · contact PI
Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)$262,485
R01 · FY2008 · CA · contact PI
Role of c-Met in SCLC and Potential for Novel Therapy$258,446
R01 · FY2008 · CA · contact PI
Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)$262,485
R01 · FY2007 · CA · contact PI
Role of c-Met in SCLC and Potential for Novel Therapy$237,141
R01 · FY2007 · CA · contact PI
Role of c-Met in SCLC and Potential for Novel Therapy$244,223
R01 · FY2006 · CA · contact PI
Role of c-Met in SCLC and Potential for Novel Therapy$250,100
R01 · FY2005 · CA
Role of c-Met in SCLC and Potential for Novel Therapy$250,100
R01 · FY2004 · CA
ABNORMALITIES OF MOTILITY OF CML CELLS$117,600
R29 · FY2001 · CA
MINIMAL RESIDUAL TUMOR IN SMALL CELL LUNG CANCER$1,632
R21 · FY2001 · CA
ABNORMALITIES OF MOTILITY OF CML CELLS$117,600
R29 · FY2000 · CA